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Abstract
Background: Among the various forms of TB, tuberculous meningitis (TBM) is the most severe, with about 30 %
mortality and 50 % of survivors left with neurological sequelae. Children suffer more frequently from TBM than
adults and outcomes are often poor due to difficulties in making the diagnosis and uncertainty regarding the best
anti-tuberculosis drug regimen. The aim of this prospective study was to describe the pharmacokinetics of
pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of children with tuberculous meningitis
treated with the standard TBM regimen.
Methods: We performed a prospective observational study of 100 consecutively treated children (≤15 years of age)
with tuberculous meningitis in Ho Chi Minh City, Vietnam. Children were treated according to the 2006 WHO
recommended pediatric treatment regimen consisting of isoniazid (5 mg/kg), rifampicin (10 mg/kg) and
ethambutol (15 mg/kg) for 8 months, with the addition of pyrazinamide (25 mg/kg) for the first 3 months and
streptomycin (15 mg/kg) for the first 2 months. Pyrazinamide, isoniazid and rifampicin concentrations were
measured in plasma at day 14 and in cerebrospinal fluid (CSF) at 1 month by HPLC-UV. A naïve-pooled non-
compartmental data analysis was used to describe the pharmacokinetic properties of drugs in the two-age groups
of children≤ 4 years or > 4 years of age.
Results: Younger children, when compared to older children, presented a higher body weight-normalized clearance
and volume of distribution, and lower median total plasma exposures for the three studied drugs with −14 %, −22 %
and −16 % for Pyrazinamide, Isoniazid and Rifampicin, respectively. In CSF, individual concentrations of isoniazid and
pyrazinamide were comparable to that in plasma in both age groups; but rifampicin concentrations were lower than
the minimum inhibitory concentration of susceptible bacteria in all but two children.
Conclusions: There is an age-dependent variation in the plasma and cerebrospinal fluid pharmacokinetics of
rifampicin, isoniazid and pyrazinamide. The safety and efficacy of higher doses of rifampicin should be
investigated for the treatment of childhood tuberculous meningitis.
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Background
Tuberculosis (TB) remains one of the major diseases
afflicting children. Among the various forms of TB, tu-
berculous meningitis (TBM) is the most severe, with
about 30 % mortality and 50 % of survivors left with
neurological sequelae [1, 2]. Children suffer more fre-
quently from TBM than adults and outcomes are often
poor due to difficulties in making the diagnosis, which
can delay treatment, and uncertainty regarding the best
anti-tuberculosis drug regimen. More than 60 years after
the development of the first anti-TB drugs, the opti-
mal treatment of childhood TBM is still uncertain and
clinical care is almost exclusively extrapolated from
studies in adults. The different multiple drug regimens
used in TBM are not uniform and mostly extrapolated
from those used in pulmonary TB, with very little sup-
portive evidence.
The first line anti-TB drugs are known to have differ-
ing cerebrospinal fluid (CSF) penetration. While plasma
and CSF exposure tend to be similar for isoniazid and
pyrazinamide, the penetration of rifampicin in CSF is
poor, as it is for ethambutol [3–6]. The death rate of
TBM patients may reflect both the poor penetration of
drugs into the brain and the poor antibacterial activity at
the current dosages. Whilst the pharmacokinetics of
first-line TB drugs has been extensively studied in
plasma in adults, only few published data describe ex-
posure of these drugs in plasma and CSF of children.
Higher doses and maybe different agents to those used
for pulmonary TB may be required to improve outcomes
from childhood TBM, but there are scant data to deter-
mine the best therapeutic approach. New randomized
controlled trials have emerged from the literature, try-
ing to assess experimental regimens in TBM [7–9].
However, evaluating modifications in a multiple drug
regimen is complex and complicated trial designs can
be required to measure and separate the effect of com-
bination treatment [10].
Our aim was to perform a naïve-pooled data non-
compartmental pharmacokinetic analysis of pyrazina-
mide, isoniazid and rifampicin in plasma and CSF in the
treatment of childhood TBM and to determine whether
age influenced drug exposure.
Methods
Patients
The study was a prospective observational study of 100
patients under 15 years of age presenting with suspected
TBM to the Pham Ngoc Thach Hospital for Tubercu-
losis and Lung Diseases (PNT) in Ho Chi Minh City.
This hospital is the tertiary referral centre for patients
with TB from the whole of southern Vietnam (popula-
tion around 45 million). All patients aged ≤15 years pre-
senting to PNT with meningitis symptoms and signs
(e.g. fever, headache, neck stiffness, vomiting, confusion,
coma, convulsions, cranial nerve palsies, hemiplegia or
paraplegia) and who were suspected to have TBM by
their attending physician were eligible to enter the study.
Patients were graded for severity at the point of study
entry. For children more than 5 years of age severity was
graded using the modified UK Medical Research Council
(MRC) criteria, based on Glasgow Coma Score (GCS).
For children less than 5 years of age, severity was graded
according to the Blantyre Coma Score (BCS).
Ethical approval for the study was granted from the
ethical review board of Pham Ngoc Thach Hospital, Viet
Nam, Health Services of Ho Chi Minh City and the
Oxford Tropical Research Ethics Committee (OxTREC),
UK. Written informed consent was obtained from the
parents or guardians of all participants.
Anti-tuberculosis drug treatment
Children diagnosed with TBM were treated with the
standard Vietnamese National TB Programme (NTP)
8-month regimen. At the time the study was initiated,
Vietnam had not yet adopted the new doses recom-
mended by WHO [11] in 2011. Therefore, children
received once daily treatment with pyrazinamide
(25 mg/kg), isoniazid (5 mg/kg), rifampicin (10 mg/
kg), ethambutol (15 mg/kg) and streptomycin (15 mg/
kg) for the first 2 months; then isoniazid, rifampicin,
ethambutol and pyrazinamide for the third month;
and then isoniazid, rifampicin and ethambutol for the
continuation phase of 5 months. Dexamethasone was
used as adjunctive therapy for the first 6 (MRC/BCS
grade I disease) or 8 (MRC/BCS grades II or III dis-
ease) weeks of treatment in all patients according to
standard practice [12].
Locally produced adult fixed dose combination (FDC)
tablets were used for treatment (Turbezid® Namha
Pharmaceutical Joint-Stock Company). These consisted
of film-coated and scored tablets containing 150 mg of
rifampicin, 75 mg of isoniazid and 400 mg of pyrazina-
mide. Each tablet was designed for ≥ 15 kg of body
weight and used a drug ratio compatible with the adult
TB regimen. Tablets were split in thirds for the lightest
patients (<5 kg), halves (5–7.5 kg), 2 thirds (7.5–10 kg)
or used as whole plus extra split for over 15 kg. Etham-
butol was given orally as a single drug tablet and
streptomycin was injected intravenously.
Pharmacokinetic sampling
Each patient enrolled in the study was asked to provide
plasma on day 1 (first day of treatment), day 14 (steady-
state), and plasma and CSF at months 1 and 3. Enrolled
patients were stratified into two groups (below and
above 4 years of age) and randomisation of plasma sam-
pling times was stratified by group. Previous admission
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patterns led us to believe that this age grouping would
deliver to groups of approximately equal size. For each
patient, two plasma samples were collected at two of ten
randomly allocated pre-specified time points (i.e. at 1, 2,
3, 4, 5, 6, 8, 12, 18 or 24 h post-dose) on each of days 1
and 14. One additional plasma sample was collected for
each patient at month 1 and 3, again at a randomly allo-
cated time points between 3 to 5 h post-dose. Each child
provided a maximum of 6 plasma samples over the trial.
CSF sampling by lumbar puncture (LP) was con-
formed to standard clinical care with CSF examination
executed to assess treatment response. LPs were per-
formed at months 1 and 3 post study entry at ran-
domly allocated time points either 3, 4 or 5 h post-
dose. Each LP was followed by a blood draw performed
within 15 min. Freshly collected clinical samples were
immediately processed and stored at −80 °C pending
bioanalysis.
Acetylator genotyping
Acetylator genotype and predicted phenotype for each
patient was determined by sequencing the second exon
of the arylamine N-acetyltransferase 2 (NAT2) gene
which contains the functional polymorphisms [13, 14].
Genomic DNA was extracted from blood using the
Nucleon Genomic DNA extraction kit (GE Healthcare,
Amersham, United Kingdom). Two primers NAT2F 5′-
TGGGCTTAGAGGCTATTT and NAT2R 5′-GAGTT
GGGTGATACATACAC were designed using Primer
Express version 2.0 software (Applied Biosystems Inc,
Foster City, CA, USA) to amplify a 768 bp sequence of
the second exon of the NAT2 gene which contains the
relevant polymorphisms (G191A, C282T, T341C, C481T,
G590A, A803G, G857A). Following purification (QIAgen
PCR purification kits, QIAGEN, United Kingdom)
amplicons were sequenced (3130xl Genetic Analyzer
Applied Biosystem, Hitachi, Singapore) and phenotypes
predicted from genotypes previously defined in a cohort
of healthy Vietnamese volunteers in a study correlating
urinary caffeine metabolites ratios with NAT2 genotypes
(data not shown) [15, 16].
Drug bioanalysis
The concentrations of pyrazinamide, isoniazid and ri-
fampicin in plasma and CSF were measured by a fully
validated HPLC method with UV detection following
the Food and Drug Administration (FDA) and Inter-
national Conference on Harmonization (ICH) recom-
mendations [17]. Ethambutol is only detectable with
mass spectrometry and was not analysed in this study.
Thawed samples (plasma or CSF) were mixed for at least
30 s and left undisturbed on the bench for further
10 min. Then, 300 μL of IS solution (Guanosine and
Phenacetine in saturated NaCl) were added to 300 μL of
sample (plasma or CSF) in a 1.5 mL microcentrifuge
tube. The tube was mixed for 15 s and left at room
temperature for 10 min followed by a centrifugation at
3000 g for 5 min. The samples were loaded into a condi-
tioned ISOLUTE-C18 50 mg/mL 96 well-plate (Biotage,
Uppsala, Sweden) and washed with 0.5 mL of saturated
NaCl until dryness. Isoniazid, pyrazinamide and guano-
sine were eluted with 2 × 250 μL of methanol–water
(10:90, v/v). A second elution containing rifampicin and
phenacetine was carried out by using 250 μL acetonitrile
followed by 250 μL methanol. Ten μL of each eluate
were injected into 2 independent equilibrated LC-UV
systems (Lachrom Elite – Hitachi – Merck system). Sep-
aration was performed on a 5 μm LichroCart 125 ×
4.6 mm Purosphere RP-18 end-capped column,
equipped with 5 μm guard column LichroCart 4 ×
4 mm, RP-18e (Merck, Darmstadt, Germany), and an
isocratic flow rate of 1 mL/min of phosphate buffer
(pH 4.2, 50 mM) and acetonitrile 0.25 % (v/v) for isonia-
zid, pyrazinamide and guanosine, and phosphate buffer
(pH 4.2, 50 mM) and acetonitrile 36 % (v/v) for rifampi-
cin and phenacetine. The chromatography time for all
assays was set to 7 min with detection at 263 nm for
isoniazid, pyrazinamide and guanosine and 247 nm for
rifampicin and phenacetine, respectively. In plasma, the
calibration ranged [lower limit of quantification (LOQ)
to upper limit of quantification (ULOQ)] from 0.2 to
80 μg/mL, 0.2 to 32 μg/mL and 0.1 to 20 μg/mL for
pyrazinamide, isoniazid and rifampicin, respectively. In
CSF, the ranges were 0.2 to 40 μg/mL, 0.2 to 32 μg/mL
and 0.1 to 16 μg/mL for pyrazinamide, isoniazid and ri-
fampicin, respectively. Triplicates of quality control
samples (low, middle and high) were analyzed within
each batch to ensure accuracy and precision through-
out the analysis. The precision of all quality control
samples were below 15 % CV during routine drug
measurements.
Naïve-pooled non-compartmental analysis
The naïve-pooled data analysis was based on plasma and
CSF data collected at the first steady-state occasion (i.e.
at day 14 for plasma samples and at month 1 for CSF
samples). Drugs reach their respective steady-states after
a minimum of 5 half-lives. With anti-TB drugs, the
steady-state is assumed to be reached after 2 weeks even
for RIF and its well described autoinduction metabol-
ism [18, 19]. We also anticipated no significant phar-
macokinetic changes between day 14 and month 1. The
concentration-time data were pooled dependent on
sampling matrix and split into 2 independent age-
groups: ≤ 4 years and > 4 years. All concentration-time
data were pooled for the following time windows: 0–
0.5, 0.5–1, 1–2, 2–3, 3–4, 4–5, 5–6, 6–8, 8–12, 12–18,
and 18–24 h post-dose. The 25th percentile (Q1), 50th
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percentile (median), and 75th percentile (Q3) of drug
concentrations were calculated within each time win-
dow. Drug measurements below the LOQ were set to
LOQ/2 to avoid bias on account of data censoring. Me-
dian concentrations and mid-time intervals were used
in the non-compartmental analysis, and Q1 and Q3
were used for graphical representation only.
Naïve-pooled concentration-time data were evaluated
using a non-compartmental analysis approach imple-
mented in WinNonlin version 6.3 (Pharsight Corporation,
California, USA). Median drug exposure up to the last
time point (AUC0-t) was calculated using the linear
trapezoidal method for ascending concentrations and
the logarithmic trapezoidal method for descending con-
centrations. The median terminal elimination rate con-
stant (λZ) was determined as the slope of the terminal
elimination phase by best-fit ordinary linear regression.
Drug exposure was extrapolated from the last observed
median concentration to time infinity by CLAST/λZ for
each individual group to compute total drug exposure
(AUC0-∞). The terminal elimination half-life (t1/2) was
calculated as ln(2)/λZ. Maximum median concentration
(CMAX) and time to CMAX (TMAX) were taken directly
from the observed data. Apparent median volume of
distribution (VZ/F) and median oral clearance (CL/F)
were computed according to standard procedures. The
wild-type minimum inhibitory concentrations (MIC)
were arbitrary chosen from reference values from the
literature [20, 21]. They were set at 12.5 mg/L, 0.2 mg/
L and 1.0 mg/L for pyrazinamide, isoniazid and rifam-
picin, respectively. These MIC values were imple-
mented in WinNonlin for the calculation of time above
MIC (T >MIC) and exposure above MIC (AUC >MIC)
as therapeutic indices. Sub-therapeutic thresholds were
applied using maximum plasma concentrations (CMAX)
associated with poor outcome in adults with pulmonary
TB [18, 22–25]. The use of these cut-off concentrations
is difficult in the context of a multiple drugs therapy
and they are still controversial and debated in the lit-
erature. However, although there are no consensus
values for sub-therapeutic thresholds associated with
TBM, or in children, they can be considered as “bio-
markers” of clinical outcome. More importantly even if
only used graphically in this study, they are able to
visualize under-exposure and compare peak concentra-
tions between observed values in children and an adult
reference. The sub-therapeutic thresholds were set at
35 μg/mL, 3 μg/mL and 8 μg/mL for pyrazinamide, iso-
niazid and rifampicin, respectively. Naïve-pooled phar-
macokinetic parameter estimates are summarized in
Tables 2 to 5, and the relative differences (%) in individ-
ual median parameter estimates were calculated be-
tween the two age strata for each drug, using the older
age group as a reference.
Results
Clinical study characteristics
One hundred children were enrolled in this study. The
overall median age of the studied children was 36 months
with the largest proportion of children (64 %) below
4 years of age. Among the 33 children ≥ 5 years of age,
16 (48 %) patients were admitted with stage I TBM ac-
cording to the MRC criteria, 11 (33 %) with stage II and
6 (18 %) with stage III. Among the remaining 67 chil-
dren < 5 years of age, 43 (64 %) were admitted with a
BCS of 4–5 (BCS I), 12 (18 %) with a BCS of 2–3 (BCS
II) and 12 (18 %) with a BCS of 0–1 (BCS III). An im-
portant proportion (39 %) of the Vietnamese children in
this study were classified as malnourished according to
the WHO growth criteria with a body mass index (BMI)
Z-score below −2 (negative two) [26]. However, a signifi-
cant weight gain occurred during the first 3 months of
treatment (Table 1). The treatment doses in mg/kg,
based on the body weight measured at enrollment, did
not show significant differences between the two age-
groups (Table 2, 3 and 5 for pyrazinamide, isoniazid and
rifampicin, respectively).
Fifteen patients (15 %) died. Ten of 64 children under
4 (16 %) vs 5 of 36 children ≥ 4 years (14 %). The major-
ity of deaths occurred in patients with advanced grades
of disease at presentation (MRC grade II or III, or BCS
from 0–3), but a single death occurred in a patient pre-
senting with MRC grade-I TBM with concomitant HIV
infection. It must be noticed that a higher proportion of
older children had definite or probable TBM (30/36:
83 %) compared to younger children (42/64: 66 %) which
might influence the respective mortality and morbidity
in each group. Eight deaths occurred within the first
6 days, six between 6 and 45 days and the last death oc-
curred at day 92. There were no significant differences
in mortality or morbidity between the two age groups.
At the end of the treatment, 6 out of 81 children (7 %)
had severe symptoms and/or required help day and
night, 21 of 81 children (26 %) had intermediate seque-
lae but independent life (modified Rankin scale from 2–
3 [12]), and 54 out of 81 children (67 %) recovered fully
(4 children did not complete the final study visit). In this
study, AST and ALT levels were measured repeatedly for
all patients for 90 days (pre-dose, 30, 60 and 90 days) or
at any time the children developed symptoms. Two out
of 99 children (2 %) met the criteria for drug-induced
liver toxicity (DILI) but no child died due to DILI in this
study.
Pharmacokinetic analysis
All pharmacokinetic blood draws were close to the pre-
specified protocol sampling times (<10 % CV for both
age-groups). The absolute difference between the actual
sampling time and mean time in the assigned window
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Table 1 Baseline characteristics and outcomes of studied children
<4 years olda >4 years oldb Total
Number of patients enrolled, n 64 36 100
Male/Female, n (male %) 36/65 (56.3) 20/36 (55.6) 56.0
Age (months) 12 (2–48) 96 (48–180) 36 (2–180)
Body weight (kg) 9.0 (4.0–15.0) 19.0 (13.5–43.0) 10.9 (4.0–43.0)
BMI (kg/m2) 15.4 (11.9–22.0) 13.3 (10.6–20.2) 14.3 (10.6–22.0)
Malnourished, n (%) 18/64 (28.1) 20/36 (55.5) 38.0
Body weight gained (kg)
after 1 month 0.5 (−0.3–2.5) 0.75 (−7.5–6.0) 0.5 (−7.5–6.0)
after 3 months 1.3 (−0.8–5.3) 2.0 (−9.0–12.5) 1.5 (−9.0–12.5)
Fast/Slow acetylator status, n (%)c 35/23 (60 %) 29/5 (85 %) 64/28 (70 %)
HIV positive, n (%)d 2/61 (3.3 %) 2/35 (5.7 %) 4/96 (4.2 %)
TBM Grade I, n (%) 43/67 (64 %) 16/33 (48 %) 59/100 (59 %)
TBM Grade II, n (%) 12/67 (18 %) 11/33 (33 %) 23/100 (23 %)
TBM Grade III, n (%) 12/67 (18 %) 6/33 (18 %) 18/100 (18 %)
TB diagnosis: Definite, n (%) 3/64 (4.7 %) 3/36 (8.3 %) 6/100 (6.0 %)
TB diagnosis: Probable, n (%) 39/64 (61 %) 27/36 (75 %) 66/100 (66 %)
TB diagnosis: Possible, n (%) 22/64 (34 %) 6/36 (17 %) 28/100 (28 %)
Death, n (%) 10/64 (16 %) 5/36 (14 %) 15/100 (15 %)
Permanent Sequelae, n (%)e 19/51 (37 %) 8/30 (27 %) 27/81 (33 %)
All values are reported as median (range) unless otherwise specified. adisease severity grade assessed in children below 5 years old by Blantyre Coma Score;
bdisease severity grade assessed in children over 5 years old by Glasgow Coma Score; c8 patients did not complete the NAT2 genotype; d4 patients out of 100 did
not complete HIV testing; esurviving patients were assessed after treatment completion at month 8 (4 were lost to follow-up)
Table 2 Pharmacokinetic non-compartmental results of pyrazinamide in children above and below 4 years of age
Pyrazinamide <4 years old >4 years old % difference
Number of patients enrolled 64 36
Body Weight (median kg - range) 9.0 (4.0–15.0) 19.0 (13.5–43.0)
Age (median months - range) 12 (2–48) 96 (48–180)
Dosage (mean - % CV) 4.70 (12.8) 5.12 (9.18) p-value: 0.0001a
CMAX (ug/mL) 30.1 37.4 −19.5
TMAX (hr) 2 3 −33.3
CL/F (L/hr) 1.09 1.88 −42
CL/F/BW (L/hr/kg) 0.12 0.1 20
V/F (L) 7.57 12.2 −37.9
V/F/BW (L/kg) 0.84 0.64 31.3
T1/2 (hr) 4.82 4.5 7.11
AUC0-∞ (hr × ug/mL) 245 284 −13.7
AUC0-∞/dosage (hr × ug/mL/(mg/kg)) 10.1 10.8 −6.2
T > MIC (hr) 7.28 8.46 −13.9
T > MIC/24 h (%) 30.3 35.2 −13.9
AUC >MIC (hr × ug/mL) 62.3 95.2 −34.6
Apart for dosage with mean and % CV, all values are reported as median (range) or as median estimates for pharmacokinetic parameters. CMAX maximum
observed plasma concentration after oral administration, TMAX observed time to reach CMAX, CL/F oral elimination clearance, CL/F/BW elimination clearance corrected by the
median body weight, V/F apparent volume of distribution, V/F/BW apparent volume of distribution corrected by the median body weight, T1/2 terminal elimination half-life,
AUC0-∞ predicted area under the plasma concentration-time curve after the last dose from zero time to infinity, T >MIC time above the minimum inhibitory concentration,
T >MIC/24 h percentage of the time above the minimum inhibitory concentration over the 24 h dose interval, AUC >MIC observed area under the plasma concentration-
time curve above the minimum inhibitory concentration. % difference is calculated with the > 4 years group used as the reference. aMann–Whitney T-test
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ranged between −8.2 min to +6.4 min for children below
4 years of age, and between −6.5 min to +0.3 min for
children above 4 years of age. The density of individual
data points used in each bin was also comparable be-
tween the two age groups (after adjusting for the differ-
ent sample size).
The median and inter-quartile range of naïve-pooled
plasma concentrations represented the central trends
and the variability of the measured concentration-time
profiles well in both age-groups for all drugs (Figs. 1, 2,
3 and 4). As seen in Tables 2, 3 4 and 5, the dosages
were in agreement with the 2006 WHO recommenda-
tions at the time of the study. However, significant dif-
ferences were found between young and old children
for all drugs but INH when the dosing of fast and slow
acetylators was compared. This is likely an inevitable
consequence of larger relative body weight differences
for younger children enhanced by the need to fit the
weight bands and the lack of uniformity when tablets
have to be split [27].
Pyrazinamide
Pooled pharmacokinetic parameters, stratified for chil-
dren above and below 4 years of age, are presented in
Table 2. Young children, as compared to older children,
showed a trend of 22 % higher body weight-normalized
elimination clearance and 31 % higher volume of distri-
bution, a 20 % lower maximum concentration but a
modest decrease of 14 % in total exposure. Total expos-
ure, normalized on dosage (mg/kg), showed a less pro-
nounced decrease with 6.3 %. However, a relatively small
decrease of 14 % in the time above MIC was seen while
the total exposure above MIC was found lower (35 %) in
young children compared to older children. The previ-
ously defined sub-therapeutic plasma concentration
threshold of 35 μg/mL was only reached by older pa-
tients [18, 28]. The distribution and accumulation of
pyrazinamide into CSF could only be assessed graphic-
ally but showed similar exposure to that in plasma,
above the wild-type MIC, in both age groups (Fig. 1).
Isoniazid
Pooled pharmacokinetic parameters, stratified for chil-
dren above and below 4 years of age, are presented in
Table 3. Young children, as compared to older children,
showed a higher body weight-normalized elimination
clearance (35 %) and volume of distribution (61 %), with
a 14 % lower maximum concentration and a 22 % lower
total exposure. Total exposure, normalized on dosage
(mg/kg), showed a less pronounced decrease of 15 %.
Similar time above MIC was seen while the total expos-
ure above MIC was lower (26 %) in young children
compared to older children. However, the previously
defined sub-therapeutic plasma concentration threshold
of 3 μg/mL [18, 23] was reached in both age groups
Table 3 Pharmacokinetic non-compartmental results of isoniazid in children above and below 4 years of age
Isoniazid <4 years old >4 years old % difference
Number of patients enrolled 64 36
Body Weight (median kg - range) 9.0 (4.0–15.0) 19.0 (13.5–43.0)
Age (median months - range) 12 (2–48) 96 (48–180)
Dosage (mean - % CV) 25.0 (12.8) 27.3 (9.17) p-value: 0.0002a
CMAX (ug/mL) 4.38 5.11 −14.3
TMAX (hr) 2 3 −33.3
CL/F (L/hr) 2.48 3.88 −36.1
CL/F/BW (L/hr/kg) 0.28 0.2 40
V/F (L) 11.3 14.9 −23.8
V/F/BW (L/kg) 1.26 0.78 61.5
T1/2 (hr) 3.17 2.66 19.2
AUC0-∞ (hr × ug/mL) 20.2 25.8 −21.8
AUC0-∞/dosage (hr × ug/mL/(mg/kg)) 4.48 5.26 −14.8
T > MIC (hr) 14.2 14.5 −1.8
T > MIC/24 h (%) 59.3 60.3 −1.79
AUC0–24 h > MIC (hr × ug/mL) 16.3 22 −25.8
Apart for dosage with mean and % CV, all values are reported as median (range) or as median estimates for pharmacokinetic parameters. CMAX maximum
observed plasma concentration after oral administration, TMAX observed time to reach CMAX, CL/F oral elimination clearance, CL/F/BW elimination clearance corrected by the
median body weight, V/F apparent volume of distribution, V/F/BW apparent volume of distribution corrected by the median body weight, T1/2 terminal elimination half-life,
AUC0-∞ predicted area under the plasma concentration-time curve after the last dose from zero time to infinity, T >MIC time above the minimum inhibitory concentration,
T >MIC/24 h percentage of the time above the minimum inhibitory concentration over the 24 h dose interval, AUC >MIC observed area under the plasma concentration-
time curve above the minimum inhibitory concentration. % difference is calculated with the > 4 years group used as the reference. aMann–Whitney T-test
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with an overall exposure in CSF close to that seen in
plasma (Fig. 2).
Isoniazid is known to be affected by acetylator status
(fast vs slow phenotype) [29–31]. A stratified analysis
was therefore performed to evaluate potential pharmaco-
kinetic differences between these two groups composed
by 35 fast and 23 slow acetylators in the young group
versus 29 fast and 5 slow for older children (Table 4 and
Fig. 3). Surprisingly, there was a higher body weight-
normalized clearance (20 %) in patients with a slow
acetylator phenotype and we observed a 12 % lower
dosage-normalized exposure. A large increase of 124 %
Fig. 1 Plasma (open circles) and CSF (grey squares) concentration-time profiles for pyrazinamide stratified for age (<4 years old [left] and > 4 years
old [right]). Continuous lines represent the median plasma concentration and broken lines represent the plasma upper and lower quartiles. Black
stars represent plasma samples with concentrations below LOQ. Sub-therapeutic threshold of 35 μg/mL; Minimum Inhibitory Concentration (MIC)
of 12.5 μg/mL; and Limit of Quantification (LOQ) of 0.2 μg/mL
Fig. 2 Plasma (open circles) and CSF (grey squares) concentration-time profiles for isoniazid stratified for age (<4 years old [left] and > 4 years old
[right]). Continuous lines represent the median plasma concentration and broken lines represent the plasma upper and lower quartiles. Black stars
represent plasma samples with concentrations below LOQ. Sub-therapeutic threshold: 3 μg/mL; Minimum Inhibitory Concentration (MIC) and
Limit of Quantification (LOQ): 0.2 μg/mL
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was also seen for body weight-normalized volume of
distribution in patients with a slow acetylator pheno-
type, resulting in a markedly increased terminal elimin-
ation half-life (87 %). However, an imbalance in the
number of fast and slow acetylators in the two age
groups might have confounded these results. Indeed,
the ratio was 60 % fast actetylators in the young age
group versus 85 % fast actetylators for the over 4 years
old (Table 1). Therapeutic plasma concentrations were
reached in both groups and there were no observed dif-
ferences in the distribution into CSF between fast and
slow acetylators.
Fig. 3 Plasma (open circles) and CSF (grey squares) concentration-time profiles for isoniazid stratified for Fast acetylators [left] and Slow acetylators
[right]. Continuous lines represent the median plasma concentration and broken lines represent the plasma upper and lower quartiles. Black stars
represent plasma samples with concentrations below LOQ. Sub-therapeutic threshold: 3 μg/mL; Minimum Inhibitory Concentration (MIC) and
Limit of Quantification (LOQ): 0.2 μg/mL
Fig. 4 Plasma (open circles) and CSF (grey squares) concentration-time profiles for rifampicin stratified for age (<4 years old [left] and > 4 years
old [right]). Continuous lines represent the median plasma concentration and broken lines represent the plasma upper and lower quartiles. Black
stars represent plasma samples with concentrations below LOQ. Sub-therapeutic threshold: 8 μg/mL; Minimum Inhibitory Concentration (MIC):
1.0 μg/mL; Limit of Quantification (LOQ): 0.1 μg/mL
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Table 4 Pharmacokinetic non-compartmental results of isoniazid in fast and slow acetylators
Isoniazid SLOW FAST % difference
Number of patients enrolleda 28 64
Body Weight (median kg - range) 10.0 (4.5–26.0) 13.0 (4.4–44.0)
Age (median months - range) 36 (6–180) 42 (2–180)
Dosage (mean - % CV) 4.82 (11.7) 4.70 (13.3) p-value: > 0.05b
CMAX (ug/mL) 4.56 4.62 −1.3
TMAX (hr) 1 2 −50
CL/F (L/hr) 2.28 2.47 −7.69
CL/F/BW (L/hr/kg) 0.23 0.19 21.1
V/F (L) 12.2 7.05 72.3
V/F/BW (L/kg) 1.21 0.54 124
T1/2 (hr) 3.69 1.98 86.4
AUC0-∞ (hr × ug/mL) 21.9 22.8 −3.78
AUC0-∞/dosage (hr × ug/mL/(mg/kg)) 4.38 4.95 −11.5
T > MIC (hr) 14.8 11.9 24.7
T > MIC/24 h (%) 61.7 49.4 24.8
AUC0–24 h > MIC (hr × ug/mL) 17.7 19.8 −10.7
aAcetylator genotype was determined in 92 patients. bMann–Whitney T-test. Apart for dosage with mean and % CV, all values are reported as median (range) or
as median estimates for pharmacokinetic parameters. CMAX maximum observed plasma concentration after oral administration, TMAX observed time to reach CMAX,
CL/F oral elimination clearance, CL/F/BW elimination clearance corrected by the median body weight, V/F apparent volume of distribution, V/F/BW apparent
volume of distribution corrected by the median body weight, T1/2 terminal elimination half-life, AUC0-∞ predicted area under the plasma concentration-time curve
after the last dose from zero time to infinity, T > MIC time above the minimum inhibitory concentration, T > MIC/24 h percentage of the time above the minimum
inhibitory concentration over the 24 h dose interval, AUC >MIC observed area under the plasma concentration-time curve above the minimum inhibitory
concentration. % difference is calculated with the > 4 years group used as the reference
Table 5 Pharmacokinetic non-compartmental results of rifampicin in children above and below 4 years of age
Rifampicin <4 years old >4 years old % difference
Number of patients enrolled 64 36
Body Weight (median kg - range) 9.0 (4.0–15.0) 19.0 (13.5–43.0)
Age (median months - range) 12 (2–48) 96 (48–180)
Dosage (mean - % CV) 9.38 (12.8) 10.2 (9.04) p-value: 0.0002a
CMAX (ug/mL) 4.9 5.96 −17.8
TMAX (hr) 2 3 −33.3
CL/F (L/hr) 4.66 7.86 −40.7
CL/F/BW (L/hr/kg) 0.52 0.41 26.8
V/F (L) 15.6 25.5 −38.9
V/F/BW (L/kg) 1.73 1.34 29.1
T1/2 (hr) 2.31 2.25 2.67
AUC0-∞ (hr × ug/mL) 21.5 25.4 −15.7
AUC0-∞/dosage (hr × ug/mL/(mg/kg)) 2.36 2.6 −9.23
T > MIC (hr) 6.89 6.66 3.45
T > MIC/24 h (%) 28.7 27.8 3.39
AUC0–24 h > MIC (hr × ug/mL) 11.7 14.7 −20.1
Apart for dosage with mean and % CV, all values are reported as median (range) or as median estimates for pharmacokinetic parameters. CMAX maximum
observed plasma concentration after oral administration, TMAX observed time to reach CMAX, CL/F oral elimination clearance, CL/F/BW elimination clearance
corrected by the median body weight, V/F apparent volume of distribution, V/F/BW apparent volume of distribution corrected by the median body weight, T1/2
terminal elimination half-life, AUC0-∞ predicted area under the plasma concentration-time curve after the last dose from zero time to infinity, T > MIC time above
the minimum inhibitory concentration, T > MIC/24 h percentage of the time above the minimum inhibitory concentration over the 24 h dose interval, AUC >MIC
observed area under the plasma concentration-time curve above the minimum inhibitory concentration. % difference is calculated with the > 4 years group used
as the reference. aMann–Whitney T-test
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Rifampicin
Overall, rifampicin presented the largest variation in the
concentration-time profiles, especially in the younger
children (Fig. 4). Pooled pharmacokinetic parameters,
stratified for children above and below 4 years of age,
are presented in Table 5. Young children, as compared
to older children, showed a higher body weight-
normalized elimination clearance (25 %) and volume of
distribution (29 %), a 18 % lower maximum concentra-
tion and a lower total exposure with 16 %. Total expos-
ure, normalized on dosage (mg/kg), showed a less
pronounced decrease of only 9 %. Similar times above
MIC were observed while the total exposure above MIC
was found lower (20 %) in young children compared to
older children. Only a few individual concentration
measurements and none of the median or interquartile
ranges reached the previously defined sub-therapeutic
plasma concentration threshold of 8 μg/mL (Fig. 4)
[24, 25]. The observed penetration of rifampicin into
CSF was very poor with only 2 individual concentra-
tion measurements above the wild-type MIC (Fig. 4).
Discussion
The naïve-pooled pharmacokinetic analysis provided a
model-independent analysis approach and was graphic-
ally proven to represent the central trends and the vari-
ability of the measured concentration-time profiles well
in both age-groups and for all drugs. Considerable vari-
ability was seen in the observed data which might be ex-
plained by the relatively large difference in age and body
weight of enrolled children. However, although a naïve
pooled data approach provides generally fairly accurate
PK estimates [32], the observed variability emphasizes
the need to evaluate these treatments on a population
level and suggests that a nonlinear mixed-effects ap-
proach might provide a more mechanistic understanding
of the variability and the influence of clinically import-
ant covariates. Pharmacokinetic parameter estimates
in this study were generally in agreement with previ-
ous studies reporting pharmacokinetic properties of
this first-line therapy in children with pulmonary TB
[31, 33–35] and TBM [4, 36, 37].
All drugs showed a higher body weight-normalized
elimination clearance in young children as compared to
older children, and a lower drug exposure was observed
in the young group. Similar results have been presented
in the literature, noticing a lower exposure in children
when compared adults, and lower exposure in young chil-
dren when compared to older children [30, 31, 38, 39].
These observations lead the revision of the pediatric
dosing regimen in TB, recommending an increased
dosage for all TB drugs in children. This is most likely
a consequence of the well-known allometric relation-
ship between body weight and clearance, and
emphasizes the need of dose adjustments in young chil-
dren with a focus on the youngest patients. In order to
produce a dosing alternative that provides an equivalent
total drug exposure in children of all age, dosing should
therefore rather be scaled with, for example, the body
surface area or the lean body weight [40, 41] . Large ob-
served variability and a model-independent analysis, as
presented in this study, do not provide a reliable tool to
suggest new dosing regimens. However, our data sup-
port the recent WHO recommendations to increase the
doses of anti-tuberculosis drugs in children with TB,
and moreover underline the importance of this in TB
meningitis. Further studies are needed urgently to evaluate
the clinical impact of the new WHO regimen, designed
for pulmonary TB, in young children with TBM.
Plasma concentrations of isoniazid and pyrazinamide
reached therapeutic levels rapidly after drug adminis-
tration. However, only a few individual concentration
measurements of rifampicin reached a putative thera-
peutic level of 8 μg/mL, suggesting that rifampicin may
still be severely under-dosed with the current dose rec-
ommendation of 15 mg/kg. TBM is primarily a disease
of the brain and it is therefore crucial that the adminis-
tered drugs are distributed from blood into the thera-
peutic site of action in sufficient concentrations to
eliminate the bacterium. Only pyrazinamide and isonia-
zid demonstrated a large distribution from plasma to
CSF with approximately equivalent drug concentrations
in plasma and CSF.
Pyrazinamide is only active at low pH which makes
definition of MIC difficult in the context of TBM [42].
The role of pyrazinamide within the neutral pH environ-
ment of the CSF compartment is unclear. It may have a
crucial role in clearing persistent metabolically dormant
bacilli within tuberculomas. However, although less fre-
quent in children, pyrazinamide is the antituberculous
agent most often implicated in the development of drug-
induced liver injuries (DILI) and consideration must
therefore be given to the risk of DILI with increased doses
of pyrazinamide when determining optimal dosage.
Isoniazid is responsible for killing the majority of the
bacteria within the first days of treatment in pulmonary
TB [43–46]. Achieving adequate drug concentrations in
CSF in the treatment of TBM is therefore likely to be
crucial in preventing early mortality and morbidity. This
emphasizes the importance of dose-optimization of iso-
niazid since body weight-normalized clearance and vol-
ume of distribution were found significantly higher in
younger children, resulting in a decreased exposure. This
is consistent with previous reports that younger children
eliminate isoniazid faster than older children and adults
[30, 47]. Patients with fast acetylator status had a modest
decreased body weight-normalized clearance of isoniazid
as compared to patients with slow acetylator status
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(Table 4). These results were unexpected, assuming fast
acetylators metabolize isoniazid more rapidly resulting
in an increased clearance. However, the results are likely
to be confounded by the greater proportion of slow acet-
ylators in the younger age group (40 %) as compared to
the older children (15 %). Young children had an overall
higher body weight-normalized clearance compared to
older children, which may have attenuated the overall
difference in isoniazid pharmacokinetics between slow
and fast acetylators. Furthermore, Thee et al. previ-
ously reported that isoniazid concentrations were not
dependent on acetylator status in South African chil-
dren below 2 years of age [31]. Maturation of the
NAT2 enzyme system with age might play an import-
ant role in the metabolism of isoniazid and/or there
might be ethnic differences in the degree to which
NAT2 genotype influences the metabolism of isoniazid.
A separate analysis demonstrated an expected 35 % in-
creased body weight-normalized clearance in children
with fast acetylator status compared to slow acetyla-
tors. It was not deemed reliable to evaluate the fast vs
slow phenotype in the older age group considering that
only 5 patients of the older children were slow acetylators.
Low concentrations of rifampicin, below the thera-
peutic threshold, were seen in CSF suggesting higher
doses of rifampicin may be more effective in the treat-
ment of childhood TBM. Rifampicin CSF drug con-
centrations are proportional to dosing and in other
forms of TB a dose-related increase in bactericidal ac-
tivity exists [4, 48] Higher dosages result in increased
early bactericidal activity [4, 49] and improved culture
conversion rates [50]. A recent Indonesian study
showed survival benefit in TBM patients with 13 mg/
kg of intravenous rifampicin and additional moxifloxa-
cin for the initial 2 weeks of treatment [7, 51]. These
two studies showed the advantage of a higher dosage
of rifampicin but here delivered intravenously. An
equivalent oral dosage is likely to be between 15 to
25 mg/kg due to the poor and variable bioavailibilty of
rifampicin [52, 53]. Children have lower exposure to
rifampicin compared to adults, given the same mg/kg
dosing. It is likely that dosages of 15–20 mg/kg in
children are required to achieve CSF concentration
well in excess of the MIC for drug-susceptible strains
and higher dosages still (≥20 mg/kg) may be required
in very young children [4]. Our findings provide
addition support for current and planned studies in-
vestigating the use of higher doses for all first-line
anti-TB drugs for TBM treatment. The 6-month inten-
sified pediatric regimen used in South Africa with ex-
cellent clinical outcomes further supports the
hypothesis that higher anti-tuberculosis drug doses,
especially of rifampicin, will improve the outcomes of
children with TBM [9].
Several limitations of this study deserve comment.
First, this was a prospective observational study using an
old and no longer recommended regimen. The higher
dose regimen recommended by WHO in 2009 was not
implemented in Vietnam until 2013. Second, only sparse
and small volume CSF sampling was possible and we
therefore had to compromise which drugs to analyse.
We chose pyrazinamide, isoniazid and rifampicin for a
technical reason: ethambutol presents a low molar ab-
sorptivity in the UV-visible spectrum and could not be
analysed by our LC-UV method. Third, in naïve pooled
data analysis, the observations from each individual are
grouped or pooled as if it was a single patient. Hence
the results from the non-compartmental analysis can
only be expressed as group median with no variation. A
risk of bias from severe outliers can arise but only with
an imbalance of data per individual, which was not the
case in this study. Naïve pooled data analysis is a sim-
plistic approach but quickly informative without the
need of specialized software and expertise from mod-
elers. However, dedicated population models able to de-
scribe the PK/PD of each drug in plasma and CSF of
children are on-going. Finally, with few CSF sampling
occasions, far from treatment initiation, the relationships
between drug exposure, bacterial killing, and clinical
outcome are difficult to assess. Most deaths occur rap-
idly within the first weeks, before any lumbar puncture
could be performed giving information on levels of
drugs in these patients.
Conclusion
In summary, this study described the pharmacokinetic
properties of isoniazid, pyrazinamide and rifampicin in
children with TBM and showed the inadequacy of the
relatively low-dose regimens, with an emphasis on the
youngest patients below 4 years of age. It is crucial that
the administered drugs distribute into the CSF in the
treatment of TBM. Only isoniazid and pyrazinamide dis-
tributed greatly into the CSF of these enrolled children.
This study provided a baseline for evaluation of the
pharmacokinetic properties of the new WHO pediatric
dosage in Vietnam, which was implemented in 2013. It re-
mains to be confirmed if the new dosing regimen is cap-
able of increasing substantially the drug exposure in the
CSF and improving clinical outcomes. More data is ur-
gently needed to establish evidence for optimal drug com-
binations and doses in the treatment of pediatric TBM.
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